Phosphorylated AMP-Activated protein kinase expression associated with prognosis for patients with gastric cancer treated with cisplatin-based adjuvant chemotherapy

Cancer Chemotherapy and Pharmacology

Volumn 70, Issue 5, 2012, Pages 735-741

  Kang, Byung Woog ^a   Jeong, Ji Yun ^a   Chae, Yee Soo ^a   Lee, Soo Jung ^a   Lee, Yoo Jin ^a   Choi, Jun Young ^a   Lee, In Kyu ^a   Jeon, Seong Woo ^a   Bae, Han Ik ^a   Lee, Da Keun ^a   Kwon, Oh Kyoung ^a   Chung, Ho Young ^a   Yu, Wansik ^a   Kim, Jong Gwang ^a  

^a Kyungpook National University Hospital   (South Korea)

Author keywords

Adjuvant chemotherapy; AMP Activated protein kinase; Cisplatin; Gastric cancer; Prognosis

Indexed keywords

CISPLATIN; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PROTEIN KINASE FYN; PYRUVATE DEHYDROGENASE KINASE; PYRUVATE DEHYDROGENASE KINASE 1; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER STAGING; CANCER TISSUE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; ETHNIC GROUP; FEMALE; FOLLOW UP; GASTRECTOMY; GENDER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KOREAN; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; SCORING SYSTEM; STOMACH ADENOCARCINOMA;

ADENOCARCINOMA; ADULT; AGED; AMP-ACTIVATED PROTEIN KINASES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; GASTRECTOMY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KOREA; LYMPH NODE EXCISION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; OXONIC ACID; PHOSPHORYLATION; PILOT PROJECTS; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL RATE; TEGAFUR; YOUNG ADULT;

EID: 84871190898     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1964-1     Document Type: Article

References (24)

1. Paoletti X, Oba K, Burzykowski T, Michiels S, Ohashi Y, Pignon JP, Rougier P, Sakamoto J, Sargent D, Sasako M, Van Cutsem E, Buyse M (2010) Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-Analysis. JAMA 303(17):1729-1737
2. Lim L, Michael M, Mann GB, Leong T (2005) Adjuvant therapy in gastric cancer. J Clin Oncol 23(25):6220-6232
3. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T, Ohashi Y (2011) Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 29(33):4387-4393
4. Yang P, Zhou Y, Chen B, Wan HW, Jia GQ, Bai HL, Wu XT (2009) Overweight, obesity and gastric cancer risk: results from a meta-Analysis of cohort studies. Eur J Cancer 45(16):2867-2873
5. Chen J (2011) Multiple signal pathways in obesity-Associated cancer. Obes Rev 12(12):1063-1070
6. Faulds MH, Dahlman-Wright K (2012) Metabolic diseases and cancer risk. Curr Opin Oncol 24(1):58-61
7. Zhao Y, Liu H, Riker AI, Fodstad O, Ledoux SP, Wilson GL, Tan M (2011) Emerging metabolic targets in cancer therapy. Front Biosci 16:1844-1860
8. Hardie DG (2011) AMP-Activated protein kinase: a cellular energy sensor with a key role in metabolic disorders and in cancer. Biochem Soc Trans 39(1):1-13
9. Yun H, Ha J (2011) AMP-Activated protein kinase modulators: a patent review (2006-2010). Expert Opin Ther Pat 21(7):983-1005
10. Wang W, Guan KL (2009) AMP-Activated protein kinase and cancer. Acta Physiol (Oxf) 196(1):55-63
11. Buckendahl AC, Budczies J, Fiehn O, Darb-Esfahani S, Kind T, Noske A, Weichert W, Sehouli J, Braicu E, Dietel M, Denkert C (2011) Prognostic impact of AMP-Activated protein kinase expression in ovarian carcinoma: correlation of protein expression and GC/TOF-MS-based metabolomics. Oncol Rep 25(4):1005-1012
12. Hadad SM, Baker L, Quinlan PR, Robertson KE, Bray SE, Thomson G, Kellock D, Jordan LB, Purdie CA, Hardie DG, Fleming S, Thompson AM (2009) Histological evaluation of AMPK signalling in primary breast cancer. BMC Cancer 9:307
13. Park HU, Suy S, Danner M, Dailey V, Zhang Y, Li H, Hyduke DR, Collins BT, Gagnon G, Kallakury B, Kumar D, Brown ML, Fornace A, Dritschilo A, Collins SP (2009) AMP-Activated protein kinase promotes human prostate cancer cell growth and survival. Mol Cancer Ther 8(4):733-741
14. Yu SY, Chan DW, Liu VW, Ngan HY (2009) Inhibition of cervical cancer cell growth through activation of upstream kinases of AMP-Activated protein kinase. Tumour Biol 30(2):80-85
15. William WN, Kim JS, Liu DD, Solis L, Behrens C, Lee JJ, Lippman SM, Kim ES, Hong WK, Wistuba II, Lee HY (2012) The impact of phosphorylated AMP-Activated protein kinase expression on lung cancer survival. Ann Oncol 23(1):78-85
16. Harhaji-Trajkovic L, Vilimanovich U, Kravic-Stevovic T, Bumbasirevic V, Trajkovic V (2009) AMPK-mediated autophagy inhibits apoptosis in cisplatin-Treated tumour cells. J Cell Mol Med 13(9B):3644-3654
17. Kim HS, Hwang JT, Yun H, Chi SG, Lee SJ, Kang I, Yoon KS, Choe WJ, Kim SS, Ha J (2008) Inhibition of AMP-Activated protein kinase sensitizes cancer cells to cisplatin-induced apoptosis via hyper-induction of p53. J Biol Chem 283(7):3731-3742
18. Kang BW, Kim JG, Chae YS, Lee YJ, Lee SJ, Moon JH, Sohn SK, Jung MK, Jeon SW, Jang YJ, Seo J, Lee YH, Kwon O, Chung HY, Yu W (2012) Pilot study of adjuvant chemotherapy with 3-week combination of S-1 and cisplatin for patients with stage II-IV (M0) gastric cancer. Invest New Drugs 30(4):1671-1675
19. Carling D, Zammit VA, Hardie DG (1987) A common bicyclic protein kinase cascade inactivates the regulatory enzymes of fatty acid and cholesterol biosynthesis. FEBS Lett 223(2):217-222
20. Hardie DG (2011) AMP-Activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev 25(18): 1895-1908
21. Saitoh M, Nagai K, Nakagawa K, Yamamura T, Yamamoto S, Nishizaki T (2004) Adenosine induces apoptosis in the human gastric cancer cells via an intrinsic pathway relevant to activation of AMP-Activated protein kinase. Biochem Pharmacol 67(10): 2005-2011
22. Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22(47):7265-7279
23. Baba Y, Nosho K, Shima K, Meyerhardt JA, Chan AT, Engelman JA, Cantley LC, Loda M, Giovannucci E, Fuchs CS, Ogino S (2010) Prognostic significance of AMP-Activated protein kinase expression and modifying effect of MAPK3/1 in colorectal cancer. Br J Cancer 103(7):1025-1033
24. Olaussen KA, Dunant A, Fouret P, Brambilla E, Andre F, Haddad V, Taranchon E, Filipits M, Pirker R, Popper HH, Stahel R, Sabatier L, Pignon JP, Tursz T, Le Chevalier T, Soria JC (2006) DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355(10): 983-991